• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

衰变加速因子(CD55)的抑制作用可减弱前列腺癌在体内的生长和存活。

Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.

作者信息

Loberg Robert D, Day LaShon L, Dunn Rodney, Kalikin Linda M, Pienta Kenneth J

机构信息

Department of Urology, University of Michigan Urology Center, Ann Arbor, MI, USA.

出版信息

Neoplasia. 2006 Jan;8(1):69-78. doi: 10.1593/neo.05679.

DOI:10.1593/neo.05679
PMID:16533428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1584292/
Abstract

Decay-accelerating factor (CD55) is a member of membrane-bound complement-regulatory proteins. CD55 expression correlates with poor survival in patients with colorectal cancer and has been implicated in the survival and tumorigenesis of blood-borne malignancies. Histologic analysis of clinical specimens from patients with advanced prostate cancer revealed an increase in CD55 expression in prostate tumor epithelial cells. CD55 was shown to be functionally active and to inhibit complement-mediated lysis in PC-3 and DU145 cells. The percentage of lysis was correlative with the CD55 expression profile observed in these prostate cancer cell lines. These data suggest that CD55 is an important regulator of prostate cancer cell survival. As a result, we have hypothesized that CD55 expression on prostate cancer cells promotes cell survival and contributes to the metastatic potential of prostate cancer cells. To determine the role of CD55 in prostate cancer tumorigenesis and metastasis, we generated PC-3(Luc) prostate cancer cells with CD55 siRNA-targeted disruption. We found that PC-3(Luc)/CD55 siRNA constructs in SCID mice resulted in a significant attenuation of overall tumor burden. Further investigation into the mechanisms of CD55-mediated tumor cell/microenvironment interaction is necessary to understand the role of CD55 in tumor cell survival and metastatic lesion formation.

摘要

衰变加速因子(CD55)是膜结合补体调节蛋白家族的一员。CD55的表达与结直肠癌患者的不良生存相关,并与血行性恶性肿瘤的生存和肿瘤发生有关。对晚期前列腺癌患者临床标本的组织学分析显示,前列腺肿瘤上皮细胞中CD55表达增加。研究表明,CD55具有功能活性,可抑制PC-3和DU145细胞中补体介导的细胞溶解。细胞溶解百分比与这些前列腺癌细胞系中观察到的CD55表达谱相关。这些数据表明,CD55是前列腺癌细胞生存的重要调节因子。因此,我们推测前列腺癌细胞上的CD55表达促进细胞存活,并有助于前列腺癌细胞的转移潜能。为了确定CD55在前列腺癌肿瘤发生和转移中的作用,我们构建了针对CD55的siRNA靶向破坏的PC-3(Luc)前列腺癌细胞。我们发现,在SCID小鼠中植入PC-3(Luc)/CD55 siRNA构建体可显著减轻总体肿瘤负担。进一步研究CD55介导的肿瘤细胞/微环境相互作用机制,对于理解CD55在肿瘤细胞存活和转移病灶形成中的作用至关重要。

相似文献

1
Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.衰变加速因子(CD55)的抑制作用可减弱前列腺癌在体内的生长和存活。
Neoplasia. 2006 Jan;8(1):69-78. doi: 10.1593/neo.05679.
2
Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.小干扰RNA定向靶向Toll样受体4可抑制人前列腺癌细胞的侵袭、存活及致瘤性。
Mol Immunol. 2009 Sep;46(15):2876-84. doi: 10.1016/j.molimm.2009.06.016. Epub 2009 Jul 29.
3
Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.肾肿瘤细胞系上CD46、CD55和CD59的表达及其在预防补体介导的肿瘤细胞裂解中的作用。
Lab Invest. 1996 Jun;74(6):1039-49.
4
Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.联合酵母β-葡聚糖和抗肿瘤单克隆抗体治疗需要通过调节衰变加速因子CD55介导的C5a中性粒细胞趋化作用。
Cancer Res. 2007 Aug 1;67(15):7421-30. doi: 10.1158/0008-5472.CAN-07-1465.
5
Potent oncolytic activity of human enteroviruses against human prostate cancer.人肠道病毒对人前列腺癌的强大溶瘤活性。
Prostate. 2008 May 1;68(6):577-87. doi: 10.1002/pros.20741.
6
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.前列腺癌细胞与成骨细胞的相互作用改变了前列腺癌中生长/存活相关基因的表达,并降低了成骨细胞中骨保护素的表达。
Clin Cancer Res. 2003 Jul;9(7):2587-97.
7
Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.补体膜调节蛋白膜辅因子蛋白(CD46)、衰变加速因子(CD55)和保护素(CD59)在人类恶性胶质瘤中的表达。
Am J Pathol. 1996 Apr;148(4):1139-52.
8
IQGAP2, A candidate tumour suppressor of prostate tumorigenesis.IQGAP2,一种前列腺肿瘤发生的候选肿瘤抑制因子。
Biochim Biophys Acta. 2012 Jun;1822(6):875-84. doi: 10.1016/j.bbadis.2012.02.019. Epub 2012 Mar 2.
9
Prognostic significance of CD55 expression in breast cancer.CD55表达在乳腺癌中的预后意义。
Clin Cancer Res. 2008 Aug 1;14(15):4780-6. doi: 10.1158/1078-0432.CCR-07-1844.
10
CD55 limits sensitivity to complement-dependent cytolysis triggered by heterologous expression of α-gal xenoantigen in colon tumor cells.CD55 限制了通过在结肠肿瘤细胞中表达α-半乳糖异种抗原引发的补体依赖性细胞溶解的敏感性。
Am J Physiol Gastrointest Liver Physiol. 2014 Jun 15;306(12):G1056-64. doi: 10.1152/ajpgi.00464.2013. Epub 2014 Apr 24.

引用本文的文献

1
Applying Unbiased, Functional Criteria Allows Selection of Novel Cyclic Peptides for Effective Targeted Drug Delivery to Malignant Prostate Cancer Cells.应用无偏倚的功能标准可筛选出新型环肽,用于向恶性前列腺癌细胞进行有效的靶向药物递送。
Pharmaceutics. 2025 Jul 1;17(7):866. doi: 10.3390/pharmaceutics17070866.
2
CD55 may be a new target for colorectal cancer treatment.CD55可能是结直肠癌治疗的一个新靶点。
Sci Rep. 2025 Jul 2;15(1):23086. doi: 10.1038/s41598-025-08491-4.
3
The decay-accelerating factor (CD55) in acute leukemia patients and its query implication in cancer pathogenesis.急性白血病患者中的衰变加速因子(CD55)及其在癌症发病机制中的研究意义
J Egypt Natl Canc Inst. 2025 May 27;37(1):42. doi: 10.1186/s43046-025-00299-7.
4
sBioSITe enables sensitive identification of the cell surface proteome through direct enrichment of biotinylated peptides.sBioSITe通过直接富集生物素化肽段实现对细胞表面蛋白质组的灵敏鉴定。
Clin Proteomics. 2023 Dec 5;20(1):56. doi: 10.1186/s12014-023-09445-6.
5
Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.单独使用拓扑替康和联合多西他赛节拍式给药抑制侵袭性前列腺癌上皮间质转化。
Cancer Res Commun. 2023 Jul 19;3(7):1286-1311. doi: 10.1158/2767-9764.CRC-22-0427. eCollection 2023 Jul.
6
Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth.雄激素调节的基质补体成分 7(C7)抑制前列腺癌生长。
Oncogene. 2023 Aug;42(32):2428-2438. doi: 10.1038/s41388-023-02759-7. Epub 2023 Jul 3.
7
Therapeutic hyperthermia regulates complement C3 activation and suppresses tumor development through HSPA5/NFκB/CD55 pathway in nasopharyngeal carcinoma.治疗性高温通过 HSP A5/NFκB/CD55 通路调节鼻咽癌中补体 C3 的激活并抑制肿瘤发展。
Clin Exp Immunol. 2023 Jul 21;213(2):221-234. doi: 10.1093/cei/uxad060.
8
CD55 in cancer: Complementing functions in a non-canonical manner.CD55 在癌症中的作用:以非规范方式发挥补体功能。
Cancer Lett. 2022 Dec 28;551:215935. doi: 10.1016/j.canlet.2022.215935. Epub 2022 Oct 7.
9
Application of Proteogenomics to Urine Analysis towards the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study.蛋白质基因组学在尿液分析中用于鉴定前列腺癌新型生物标志物的应用:一项探索性研究。
Cancers (Basel). 2022 Apr 15;14(8):2001. doi: 10.3390/cancers14082001.
10
Comparing Urinary Glycoproteins among Three Urogenital Cancers and Identifying Prostate Cancer-Specific Glycoproteins.三种泌尿生殖系统癌症中尿糖蛋白的比较及前列腺癌特异性糖蛋白的鉴定
ACS Omega. 2022 Mar 8;7(11):9172-9180. doi: 10.1021/acsomega.1c05223. eCollection 2022 Mar 22.

本文引用的文献

1
Analysis of membrane-bound complement regulatory proteins in prostate cancer.前列腺癌中膜结合补体调节蛋白的分析
Urology. 2005 Dec;66(6):1321-6. doi: 10.1016/j.urology.2005.06.094.
2
Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer.前列腺素E2调节结直肠癌中的补体抑制剂CD55/衰变加速因子。
J Biol Chem. 2005 Jan 7;280(1):476-83. doi: 10.1074/jbc.M407403200. Epub 2004 Nov 1.
3
MHC class I down-regulation: tumour escape from immune surveillance? (review).MHC I类分子下调:肿瘤逃避免疫监视?(综述)
Int J Oncol. 2004 Aug;25(2):487-91.
4
Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells.颗粒酶A和B在人细胞毒性淋巴细胞亚群及调节性T细胞中的差异表达
Blood. 2004 Nov 1;104(9):2840-8. doi: 10.1182/blood-2004-03-0859. Epub 2004 Jul 6.
5
Loss of CD55 is associated with aggressive breast tumors.CD55缺失与侵袭性乳腺肿瘤相关。
Clin Cancer Res. 2004 Apr 15;10(8):2797-803. doi: 10.1158/1078-0432.ccr-1073-03.
6
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.前列腺癌骨转移会促进溶骨和成骨活动。
J Cell Biochem. 2004 Mar 1;91(4):718-29. doi: 10.1002/jcb.10662.
7
The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense.表皮生长因子-七次跨膜(EGF-TM7)受体CD97是中性粒细胞迁移和宿主防御所必需的。
J Immunol. 2004 Jan 15;172(2):1125-31. doi: 10.4049/jimmunol.172.2.1125.
8
In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice.免疫缺陷小鼠体内转移性前列腺癌的可视化及疾病进展的定量分析
Cancer Biol Ther. 2003 Nov-Dec;2(6):656-60.
9
Loss of CD59 expression in breast tumours correlates with poor survival.乳腺肿瘤中CD59表达缺失与生存率低相关。
J Pathol. 2003 Aug;200(5):633-9. doi: 10.1002/path.1357.
10
Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients.补体调节蛋白CD55的表达增强预示着结直肠癌患者的预后不良。
Cancer Immunol Immunother. 2003 Oct;52(10):638-42. doi: 10.1007/s00262-003-0402-y. Epub 2003 Jun 14.